proteins 4 that traverse the secretory apparatus and is important in many normal and pathologic settings [5] [6] [7] [8] . Nonetheless, little is known about either the repertoire of O-glycans or how specific O-glycan structures regulate biology, largely because of a lack of effective technologies for O-glycomics. In contrast to N-glycans, which can be released enzymatically, O-glycans require chemical strategies for their release-primarily alkaline β-elimination, which is inefficient, is potentially biased, may result in O-glycan degradation via peeling reaction and requires extensive expertise not available in most laboratories 9 .
To address these challenges, here we describe a novel method for profiling and amplifying mucin-type O-glycans from living cells, termed Cellular O-Glycome Reporter/Amplification (CORA). CORA provided ~100-1,000-fold enhanced sensitivity and much cleaner MS profiles of O-glycans compared to conventional analyses, and it revealed O-glycans not seen by classic approaches in a variety of cancer and primary cells. Using CORA, we identified 76 O-glycans in a variety of cell types, including O-glycans observed by traditional alkaline β-elimination-MS.
results cells take up Ac 3 GalnAc-a-o-Bn and secrete Bn-o-glycans
Mucin-type O-glycan biosynthesis begins with the transfer of GalNAc to Ser or Thr residues in glycoproteins to generate GalNAc-α1-O-Ser or -Thr (Tn antigen), which T-synthase extends to the dominant core 1 O-glycan Gal-β3-GalNAc-α1-O-Ser or -Thr.
To assess the repertoire of glycosyltransferases and glycosylation reactions in the secretory pathway for the O-glycome, we developed a chemical O-glycan precursor, peracetylated benzyl (Bn)-α-GalNAc (Ac 3 GalNAc-α-Bn), which is taken up by living cells, deacetylated, modified by native glycosyltransferases in the presence of nucleotide sugar donors in the secretory pathway, and then secreted into media (Fig. 1) . Bn-α-GalNAc structurally mimics the precursor GalNAc-α1-O-Ser or -Thr (Tn antigen) in O-glycoproteins 10 and was previously used in vitro as an acceptor for T-synthase and core 3 GnT 11, 12 .
Prior studies have shown that monosaccharides linked to hydrophobic aglycones can prime glycan biosynthesis 13, 14 .
Protein o-glycosylation has key roles in many biological processes, but the repertoire of o-glycans synthesized by cells is difficult to determine. here we describe an approach termed cellular o-Glycome reporter/Amplification (corA), a sensitive method used to amplify and profile mucin-type o-glycans synthesized by living cells. cells convert added peracetylated benzyl-a-n-acetylgalactosamine to a large variety of modified o-glycan derivatives that are secreted from cells, allowing for easy purification for analysis by hPlc and mass spectrometry (ms). relative to conventional o-glycan analyses, corA resulted in an ~100-1,000-fold increase in sensitivity and identified a more complex repertoire of o-glycans in more than a dozen cell types from Homo sapiens and Mus musculus. Furthermore, when coupled with computational modeling, corA can be used for predictions about the diversity of the human o-glycome and offers new opportunities to identify novel glycan biomarkers for human diseases.
Protein glycosylation is a common post-translational modification in all animals that helps to create post-genomic diversity 1 , but systems-level approaches for glycomics are lacking in most biological settings. A primary need is simple and sensitive technology that can be used to analyze all glycans synthesized by cells (the cellular glycome) 2 . This type of analysis has been challenging because of the diversity and complexity of glycans, the low abundance of certain glycan species, the poor sensitivity of existing glycomics approaches and the lack of efficient and unbiased strategies for releasing glycans from complex samples. Current technologies for evaluating glycans require relatively large amounts of biological samples for detailed structural analyses, which limits their widespread application. One way to at least partly overcome these challenges would be to 'amplify' the glycome, similar to what is done in PCR-hybridization-based technologies for the genome 3 . Such amplification technology would allow analysis of microscale samples of biological material, facilitating clinical and biological discovery.
One of the most common types of protein glycosylation is mucin-type O-glycosylation (R-GalNAc-α1-O-Ser or -Thr, where R represents extended structures), which is present on >80% of We hypothesized that Bn-α-GalNAc at low concentrations could be used as a surrogate acceptor by T-synthase to promote the formation of free Bn-O-glycans representing the cellular O-glycome. We used Ac 3 GalNAc-α-Bn, a more hydrophobic derivative of Bn-α-GalNAc (Supplementary Fig. 1a) , to enhance cellular uptake as shown for other peracetylated carbohydrate compounds 14, 15 and predicted that upon entry into cells, Ac 3 GalNAc-α-Bn would become activated by cytosolic esterases to regenerate Bn-α-GalNAc. Bn-α-GalNAc would then be transported into the secretory pathway, modified by glycosyltransferases and secreted into media as biosynthetic Bn-O-glycans that could be easily purified and analyzed by MS (Fig. 1) .
We cultured adherent (HEK293) and suspension (Molt-4) cells in complete media containing 50 µM Ac 3 GalNAc-α-Bn or vehicle (dimethyl sulfoxide (DMSO)) for 3 d. Putative Bn-O-glycans from the media were separated from larger material with a cutoff membrane, purified by C18 chromatography, permethylated and analyzed by MALDI-TOF-MS. Here as elsewhere, we analyzed only the permethylated nonsulfated and/or nonphosphorylated glycans. We observed clean MALDI-TOF profiles with Bn-O-glycan compositions corresponding to core 1-and core 2-based structures (Supplementary Fig. 2 ) from cells cultured with Ac 3 GalNAc-α-Bn but not from cells cultured with DMSO, indicating efficient uptake and modification of the O-glycan precursor by glycosyltransferases in vivo.
To assess whether peracetylation of Bn-α-GalNAc enhances uptake and subsequent sensitivity, we incubated breast cancer cells (MDA-MB-231) with 0-250 µM Ac 3 GalNAc-α-Bn or Bn-α-GalNAc for 3 d. We observed Bn-O-glycans with the predicted sialylated core 2 structure at concentrations as low as 25 µM for Ac 3 GalNAc-α-Bn, but only at the highest concentration of 250 µM for Bn-α-GalNAc (Supplementary Fig. 3) . Further, peracetylation of Bn-α-GalNAc was stable in complete media for at least 3 d (Supplementary Fig. 4) . Thus, peracetylation improved sensitivity, and at such low concentrations potential side effects should be limited, as explored below.
To optimize conditions, we cultured MDA-MB-231 cells with 0-250 µM Ac 3 GalNAc-α-Bn for 2-4 d. Bn-O-glycans in culture media were seen at all time points and in culture conditions with as little as 5 µM Ac 3 GalNAc-α-Bn for 2 d (Supplementary Fig. 5 ), and their profiles were stable over time. Remarkably, increasing the Ac 3 GalNAc-α-Bn concentration shifted abundance from disialylated to monosialylated core 2 ( Supplementary Fig. 5d ), supporting observations that glycosyltransferase:substrate ratios drive glycan microheterogeneity 16 . Thus, CORA should be performed with low concentrations of Ac 3 GalNAc-α-Bn. For most subsequent studies, we incubated cells with 50 µM Ac 3 GalNAc-α-Bn for 3 d. At these conditions, Ac 3 GalNAc-α-Bn was not toxic to cells (Supplementary Fig. 6 ), did not alter cellular morphology or granularity (Supplementary Fig. 7 ) and did not alter cell surface O-or N-glycosylation ( Supplementary Figs. 8 and 9) , and Bn-O-glycans were stable after secretion from cultured cells (Supplementary Fig. 10 ).
synthesis of core 1-based Bn-o-glycans requires t-synthase
To confirm that Bn-α-GalNAc can be used only by glycosyltransferases involved in mucin-type O-glycan biosynthesis, and not in other, irrelevant or unknown pathway(s), we performed CORA on cells with mutant or wild-type C1galt1c1 (Cosmc), a chaperone known to be essential for T-synthase activity 17 npg when we administered Ac 3 GalNAc-α-Bn (Fig. 2) . Furthermore, cells incubated with the isomer Ac 3 GlcNAc-β-Bn ( Supplementary Fig. 1b ) secreted no Bn-O-glycans or only the simple trisaccharide Neu5Ac-Gal-GlcNAc-Bn ( Supplementary  Fig. 11 ), indicating that Ac 3 GalNAc-α-Bn is specific for mucin-type O-glycans.
Accuracy of corA
We compared O-glycome profiles obtained via CORA to profiles from β-elimination available through the Consortium for Functional Glycomics (CFG) database (http://www.functionalglycomics.org).
We analyzed WEHI-3 and HL-60 cells because they have complex O-glycomes with distinctive structures such as Cad ( G a l NAc -β 1 , 4 -( α 2 , 3 -Ne u 5 Ac ) G a l -β1,3/4-R) and extended poly-N-acetyllactosamines ([3Gal-β1,4-GlcNAc-β1] n ) that are challenging to detect by β-elimination of lysates but are observed on purified glycoproteins 18, 19 . MALDI-TOF-MS and MS/MS profiles ( Fig. 3 and Supplementary Figs. 12-14) showed that WEHI-3 and HL-60 cells produced 40 and 11 glycan structures, respectively, including sialylated core 1-and core 2-based glycans for both cells and Cad antigen in WEHI-3 cells (Fig. 3a) . CORA detected most of the compositions seen in β-eliminated samples (12 of 13 for WEHI-3 cells and 4 of 7 for HL-60 cells) as well as many additional compositions (16 for WEHI-3 cells (Fig. 3b,c) and 6 for HL-60 cells (Supplementary Fig. 12b,c) ) that were generally the most complex, including poly-N-acetyl-lactosamines with approximately three repeats and proposed I antigen. The four masses observed by β-elimination but not CORA (Fig. 3b,c and Supplementary  Fig. 12b,c) were core 1-and core 2-based glycans lacking terminal sialylation, and therefore were probably biosynthetic intermediates, as might be observed for glycoproteins within an intermediate Golgi compartment before secretion.
To confirm our results, we repeated the experiments twice and obtained nearly identical O-glycome profiles ( Supplementary  Fig. 15) . We also performed electrospray ionization MS and obtained results similar to those from MALDI-MS ( Supplementary  Fig. 16 ). We evaluated a range of cell types (Supplementary Table 1) with diverse glycosyltransferases (as exemplified by C2GnT1-3; Supplementary Fig. 17 ) and obtained O-glycome profiles from all the cells, indicating that Bn-α-GalNAc can access most if not all of the O-glycan machinery. Thus, CORA reflects the cellular O-glycome, which is relatively stable under optimal culture conditions. sensitivity of corA The β-elimination used for O-glycan release often requires ≥10 7 cells and produces many unassignable peaks 20 . To determine how many cells are needed to get clean, interpretable profiles with CORA, we profiled four cell lines, each seeded at 5 × 10 5 , 10 5 and 2 × 10 4 cells. We obtained O-glycomes from all lines seeded at ≥10 5 cells and from three of four lines seeded at 2 × 10 4 cells (Fig. 4 and Supplementary Fig. 18) . Notably, profiles did not change with different cell numbers. The detection of Bn-O-glycans from 2 × 10 4 cells cultured for 3 d (to a total of ~8 × 10 4 cells, assuming ~24-h doubling times) represents an ~100-1,000-fold increase in sensitivity compared to β-elimination.
Profiling the o-glycomes of mouse and human primary cells
Because primary cells differ metabolically from cancer cells 21 , we validated CORA on primary human and mouse cells. First we profiled immortalized murine pulmonary endothelial cells (mPECs) Fig. 19a,b) . Next we isolated Tn − mPECs from mice (Tie2-Cre − ;Cosmc F/y ) and performed CORA ( Supplementary  Fig. 19c,d) . Glycan structures were similar in immortalized and primary mPECs, except for a glycan with the disialyl motif found only in the primary cells. However, the relative abundances of O-glycans differed in these two types of mPECs, suggesting that transformation may alter glycan biosynthesis, as has been demonstrated in human tumors 23 . Next, we evaluated primary human dermal fibroblasts and human umbilical vein endothelial cells (HUVECs) (Fig. 5 and Supplementary Figs. 20 and 21) . HUVECs produced 43 O-glycan structures, including those containing poly-N-acetyllactosamine, Lewis structures, blood group antigens and I antigen, as confirmed by MS/MS (Fig. 5 and Supplementary Figs. 20  and 21) . Fibroblasts also produced at least 18 glycans (with different masses), including poly-N-acetyl-lactosamine, Lewis structures and blood group antigens (Supplementary Figs. 20b  and 22) . The remarkable diversity of O-glycans in these cells indicates their potential importance. Figs. 12-14 and 21) . Although to our knowledge this is the first report of extended core 1 on HL-60 cells and of VIM-2 and disialic acid on O-glycans from myelocytic cells, these epitopes have been observed in related contexts or structures, indicating that they are biosynthetically reasonable products [24] [25] [26] .
The I antigen replaces i antigen on red blood cells after embryogenesis but has not been identified on O-glycans from other cell lineages previously, except in secretions 27 . The discovery of I antigen on O-glycans from two distinct non-red blood cell lineages suggests that this may be a common yet unappreciated structure. We have no explanation as to why I antigen has not been observed on O-glycans from these cell lines before, except that in general the amounts of O-glycans released by β-elimination are insufficient for the identification of larger O-glycans in the highmass range, and when larger O-glycans are identified, MS/MS usually is not feasible. CORA permits analyses of small numbers of cells because the cells continuously produce more Bn-Oglycans, thereby amplifying their O-glycomes.
evaluating cellular o-glycome complexity with corA
The complete repertoire of O-glycans in human and animal cells is not known. Here we analyzed 18 cell lines, including primary cells Fig. 23a,b and Supplementary Table 2 ) and determined that a few outstanding cell lines encompassed most of the complexity of all 18 O-glycomes (Supplementary Fig. 23c ). We developed a computational model to determine the number of distinct O-glycan compositions observed on average from a given number of cell lines and predicted that the estimated 200 cell types in the human body would produce 235 distinct compositions ( Supplementary  Fig. 24 ). Using the observation above that the number of glycan structures may be 1.6-fold greater than the number of compositions, we predicted that there are 1.6 (76 structures divided by 48 compositions) × 235 = 376 nonsulfated and/or nonphosphorylated structurally different O-glycans in the human body. Although speculative to a degree, to our knowledge this is the first estimate of the size of the human cellular O-glycome based on comparative cellular O-glycomics, providing a roadmap for comprehensive sequencing of the human cellular O-glycome.
discussion
CORA is an approach for both amplifying and profiling the mucin-type O-glycome in living cells. Its high sensitivity and amplification enabled us to identify novel complex O-glycans, which were not seen in the β-elimination-released samples, indicating that β-elimination might not provide enough material for MS or MS/MS evaluation of these low-abundance species. For example, MS analyses of β-eliminated O-glycans from WEHI-3 cells have not identified sialyl-Le X on core 2 O-glycans, a critical component on PSGL-1 recognized by P-selectin, which binds WEHI-3 cells. However, this minor structure was previously confirmed by enrichment analysis 19 , and here it was detected by CORA, which directly demonstrates the improved sensitivity of CORA with respect to conventional methods. Thus the novel structures we identified are natural O-glycans, mostly present on glycoproteins at low abundance. CORA using Ac 3 GalNAc-α-Bn is specific for O-glycans, as Cosmc-deficient cells do not produce Bn-O-glycans and culturing cells with the isomer Ac 3 GlcNAc-β-Bn produced no glycans or a trisaccharide (Sia-Gal-GlcNAc-Bn) only. The latter result suggests that the enzymes responsible for poly-N-acetyl-lactosamine production, I antigen synthesis and α3-fucosylation are relatively specific to extended O-glycans in the cell lines examined. We found it interesting that CORA was effective at low concentrations (<250 µM) and short incubation times with no observed effect on cellular properties or glycosylation. Prior studies showed that treatment of cells with high concentrations of Bn-α-GalNAc for O-glycan inhibition produces mainly small Gal-β3-GalNAc-α1-O-Bn and sialyl-Gal-β3-GalNAc-α1-O-Bn derivatives 28, 29 . However, our success with CORA using low concentrations of this new Ac 3 GalNAc-α-Bn derivative as a precursor indicates that it is readily taken up by live cells, converted to Bn-α-GalNAc, efficiently used by T-synthase and further accessed by a wide range of enzymes in the secretory pathway, including the most terminal types of glycan modifications and extensions. It is noteworthy that this approach defines the global ability of cells to make O-glycans but might not always reflect their natural relative abundances, which can be influenced by the concentration of protein substrates or expression of O-glycosylated polypeptide cores.
This approach could allow for assessment of the total diversity and repertoire of O-glycans in an animal O-glycome. Recent studies using transfected CHO cells engineered to express all major O-glycan core structures, along with chemical release techniques, identified ~70 different glycan structures 30 . The repertoire of O-glycans is likely much larger, as there are nearly 1,000 mucintype O-glycan determinants, with probably <500 nonsulfated O-glycans 31 . In this regard, our computational modeling allowed us to predict the size of the nonsulfated and/or nonphosphorylated animal O-glycome as including ~376 distinct glycan structures. What drives this diversity? Amplification of an entire O-glycome from a simple chemical precursor suggests that the biosynthetic machinery, and not diverse protein substrates, largely drives O-glycan heterogeneity.
An advantage of CORA is that live cells are used to generate the O-glycome, but the cells can also be analyzed by conventional techniques afterward if desired for comparative analyses. Advances in cell and organoid culture have enabled culture of many normal and diseased tissues [32] [33] [34] [35] , yet glycan release is often not sufficiently sensitive for analyses of such precious specimens. CORA could enable researchers to address this challenge by allowing amplification of the glycome of these cells in addition to high-throughput analysis of tumor cells. Although we limited our analyses to mucin-type O-glycans, CORA may be a general strategy for amplifying and profiling many classes of glycosylation, with appropriate precursors. Although we used small numbers of cells for glycan analysis, large numbers of cells in continuous culture could also be used as glycan-biosynthesis factories to prepare any and all natural O-glycans, even those difficult to synthesize chemically. Bn-O-glycans or their derivatives could be isolated to generate therapeutic glycans, to test the roles of unusual glycans in cell recognition or growth, or for display in glycan microarrays. Amplification of the O-glycome by CORA is a new paradigm in cellular glycomics that will make new types of investigations possible in a wide range of basic and clinical settings to give new insights into the role of O-glycans in physiology and disease. methods Methods and any associated references are available in the online version of the paper. 
